| Dr Luong M Banh, MD | |
|
1026 A Avenue Ne, St. Luke's Hospitalist Program, Cedar Rapids, IA 52402 | |
| (319) 368-5970 | |
| (319) 368-5973 |
| Full Name | Dr Luong M Banh |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 18 Years |
| Location | 1026 A Avenue Ne, Cedar Rapids, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457560609 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 39131 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital | Iowa city, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Hospital Iowa City Iowa | 2062302748 | 19 |
| State University Of Iowa | 7618884230 | 1476 |
News Archive
The states are collecting record amounts of revenue from the 1998 tobacco settlement and tobacco taxes, but have cut funding for programs to reduce tobacco use by more than 15 percent in the past year, according to a report released today by a coalition of public health organizations.
Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 2 days ago
| Entity Name | State University Of Iowa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477554814 PECOS PAC ID: 7618884230 Enrollment ID: O20031107000060 |
News Archive
The states are collecting record amounts of revenue from the 1998 tobacco settlement and tobacco taxes, but have cut funding for programs to reduce tobacco use by more than 15 percent in the past year, according to a report released today by a coalition of public health organizations.
Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 2 days ago
| Entity Name | St Lukes Jones Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942397328 PECOS PAC ID: 4688572811 Enrollment ID: O20031226000198 |
News Archive
The states are collecting record amounts of revenue from the 1998 tobacco settlement and tobacco taxes, but have cut funding for programs to reduce tobacco use by more than 15 percent in the past year, according to a report released today by a coalition of public health organizations.
Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 2 days ago
| Entity Name | Mercy Hospital Iowa City Iowa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124089347 PECOS PAC ID: 2062302748 Enrollment ID: O20040317000382 |
News Archive
The states are collecting record amounts of revenue from the 1998 tobacco settlement and tobacco taxes, but have cut funding for programs to reduce tobacco use by more than 15 percent in the past year, according to a report released today by a coalition of public health organizations.
Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 2 days ago
| Entity Name | Cogent Healthcare Of Iowa, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982654497 PECOS PAC ID: 3779517941 Enrollment ID: O20050927000304 |
News Archive
The states are collecting record amounts of revenue from the 1998 tobacco settlement and tobacco taxes, but have cut funding for programs to reduce tobacco use by more than 15 percent in the past year, according to a report released today by a coalition of public health organizations.
Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Luong M Banh, MD 1026 A Avenue Ne, St. Luke's Hospitalist Program, Cedar Rapids, IA 52402 Ph: (319) 368-5970 | Dr Luong M Banh, MD 1026 A Avenue Ne, St. Luke's Hospitalist Program, Cedar Rapids, IA 52402 Ph: (319) 368-5970 |
News Archive
The states are collecting record amounts of revenue from the 1998 tobacco settlement and tobacco taxes, but have cut funding for programs to reduce tobacco use by more than 15 percent in the past year, according to a report released today by a coalition of public health organizations.
Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".
› Verified 2 days ago
Alice Xu, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1026 A Ave Ne, Cedar Rapids, IA 52402 Phone: 319-368-5970 Fax: 319-368-5973 | |
Mr. Amit Kumar Dahiya, M.D Hospitalist Medicare: Medicare Enrolled Practice Location: 1026 A Ave Ne, Cedar Rapids, IA 52402 Phone: 313-349-9055 | |
Dr. Amit Pathak, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1026 A Ave Ne, Cedar Rapids, IA 52402 Phone: 319-369-7211 | |
Dr. Anna Duke, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 1026 A Ave Ne, Cedar Rapids, IA 52402 Phone: 319-368-5970 Fax: 319-368-5973 | |
Naomi Vather-wu, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1026 A Ave Ne, Cedar Rapids, IA 52402 Phone: 319-368-5970 Fax: 319-368-5973 | |
Nicketa Burchell, DNP Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 1026 A Ave Ne, Cedar Rapids, IA 52402 Phone: 310-369-7211 |